Novavax Inc (NVAX) is experiencing a dip in its stock value as a broader negative sentiment impacts COVID-19 vaccine producers following Moderna Inc’s (MRNA) disappointing second-quarter financial results and reduced revenue forecast. Moderna reported a substantial loss per share in the second quarter, falling well below analyst predictions. The company also revised its 2025 revenue outlook downwards due to a decrease in demand for its COVID-19 vaccine, leading to a year-over-year sales decline of 41%.
The adverse report from Moderna has created a shadow over the entire sector, prompting investors to turn their attention to Novavax’s upcoming earnings report, scheduled to be released before the market opens on Wednesday, August 6. Analysts currently anticipate Novavax to report a quarterly loss per share of 6 cents with revenue around $156.30 million. Despite Novavax’s recent positive preclinical data on its H5N1 bird flu vaccine, market concerns are primarily focused on the financial sustainability within the COVID-19 market.
Investors are eagerly awaiting Novavax’s financial results to assess revenue stability and receive updates on its pipeline progress, aiming to understand whether it can navigate the challenges currently faced by Moderna and other industry peers. Based on Benzinga Edge stock rankings, Novavax is currently displaying a bearish technical profile, with weak momentum and negative price trend signals across various timeframes. The stock’s current value score indicates it is neither significantly overvalued nor undervalued at its existing price.
As of the latest data, NVAX shares are down by 3.23% to $6.43, with a 52-week high of $15.22 and a low of $5.01. Investors interested in participating in Novavax’s market can consider buying shares through a brokerage account, which may offer the option of purchasing fractional shares to own a portion of the stock. For those looking to bet against the company, the process involves using an options trading platform or a broker to short sell shares or engage in options trading to potentially profit from a decline in share price.
Key Takeaways:
– Novavax is facing stock declines amid sector-wide concerns triggered by Moderna’s financial woes.
– Investors are closely monitoring Novavax’s upcoming earnings report for insights into revenue stability and pipeline updates.
– Novavax exhibits a bearish technical profile based on Benzinga Edge stock rankings.
– Individuals interested in Novavax’s market can buy shares through a brokerage account or explore options trading to bet against the company.
Read more on benzinga.com